**Background**
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques in the brain. A key step in the production of these plaques is the cleavage of the amyloid precursor protein (APP) by the γ-secretase complex, which generates various Aβ peptides, including the highly aggregation-prone Aβ42. Reducing the generation of Aβ42 while maintaining the normal physiological functions of γ-secretase, such as Notch signaling, is a critical goal in the development of therapeutic agents for Alzheimer’s disease. In this context, we will introduce a reversible γ-secretase inhibitor – Sulindac sulfide.
**Definition**
Sulindac sulfide is a noncompetitive γ-secretase inhibitor with an IC50 value of 20.2 μM for γ42-secretase activity.
**In Vitro Studies**
According to the Sulindac sulfide description, this compound acts as a reversible inhibitor targeting the γ-secretase complex. Sulindac sulfide in vitro studies demonstrate that treatment with 100 μM of the compound induces cell death, presumably via apoptosis, leading to a marked decrease in total protein expression and Aβ generation. Specifically, the IC50 value for the secretion of Aβ42 is 30.6 ± 2.8 μM. Notably, unlike other compounds such as naproxen, Sulindac sulfide inhibits γ42-secretase activity in a dose-dependent manner without affecting Notch cleavage up to 100 μM.
The Sulindac sulfide biological activity has been further evaluated across various cell lines. In CHO cells expressing human APP and presenilin-1, the compound inhibited Aβ42 production with an IC50 of 34 μM. In HEK293 cells co-overexpressing the APP Swedish mutant, it inhibited Aβ40 and Aβ42 production with IC50 values of 215 μM and 82.5 μM, respectively, while inhibiting Notch cleavage with an IC50 of 53 μM. Additionally, the compound exhibits significant cytotoxicity and anti-proliferative effects in several cancer cell lines, including COLO 320 (IC50 = 38.7 μM), MIA PaCa-2 (IC50 = 146 μM), and MDA-MB-231 (EC50 = 209 μM), suggesting its potential application in Sulindac sulfide Cancer research. Furthermore, anti-proliferative activity was observed in MDCK cells (IC50 = 180-200 μM), NIH3T3 fibroblasts (IC50 = 350 μM), and SW480 cells (IC50 = 200 μM). In conclusion, Sulindac sulfide is a noncompetitive and reversible γ-secretase inhibitor that preferentially reduces the generation of Aβ42.
Keywords
Sulindac sulfide, 49627-27-2, cis-Sulindac sulfide, Drug Metabolite, γ-secretase, Gamma secretase, Inhibitor, inhibitor, inhibit
References